Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban
Authors:
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Journal of Cardiology
- Vol. 70 (3) , 244-249
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxabanJournal of Cardiology, 2015
- Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral AnticoagulantsJACC, 2014
- Rivaroxaban in Clinical Practice for Atrial Fibrillation With Special Reference to Prothrombin TimeCirculation Journal, 2014
- Performance of coagulation tests in patients on therapeutic doses of rivaroxabanThrombosis and Haemostasis, 2014
- Monitoring plasma levels of factor Xa inhibitors: how, why and when?Expert Review of Hematology, 2013
- Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generationClinical Chemistry and Laboratory Medicine (CCLM), 2012
- Rivaroxaban vs. Warfarin in Japanese Patients With Atrial FibrillationCirculation Journal, 2012
- Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjectsEuropean Journal of Clinical Pharmacology, 2005
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClinical Pharmacology & Therapeutics, 2005
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976